US Congress to debate another bill to rein in drug prices

11 October 2019
drug_money_man_stock_large

US trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has raised objections to a drug pricing plan outlined by House Speaker Nancy Pelosi.

The plan, which Ms Pelosi outlined in a press conference in September, would permit the federal government to negotiate the prices hundreds of branded products, including insulin, for Medicare beneficiaries.

In addition, drugmakers would be compelled to either offer the negotiated prices to private insurers or pay a penalty.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical